184 related articles for article (PubMed ID: 27693595)
21. Clinical trial simulation to assist in COPD trial planning and design with a biomarker-based diagnostic: when to pull the trigger?
Gold DL; Dawson M; Yang H; Parker J; Gossage DL
COPD; 2014 Apr; 11(2):226-35. PubMed ID: 24111823
[TBL] [Abstract][Full Text] [Related]
22. The matrikine PGP as a potential biomarker in COPD.
Abdul Roda M; Fernstrand AM; Redegeld FA; Blalock JE; Gaggar A; Folkerts G
Am J Physiol Lung Cell Mol Physiol; 2015 Jun; 308(11):L1095-101. PubMed ID: 26033353
[TBL] [Abstract][Full Text] [Related]
23. The Promise of Observational Studies (ECLIPSE, SPIROMICS, and COPDGene) in Achieving the Goal of Personalized Treatment of Chronic Obstructive Pulmonary Disease.
Rennard SI
Semin Respir Crit Care Med; 2015 Aug; 36(4):478-90. PubMed ID: 26238636
[TBL] [Abstract][Full Text] [Related]
24. Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease.
Wang H; Yang T; Li D; Wu Y; Zhang X; Pang C; Zhang J; Ying B; Wang T; Wen F
Int J Chron Obstruct Pulmon Dis; 2016; 11():2369-2376. PubMed ID: 27713627
[TBL] [Abstract][Full Text] [Related]
25. Anti-
Banerjee S; Bhattacharyya P; Mitra S; Kundu S; Panda S; Chatterjee IB
Int J Chron Obstruct Pulmon Dis; 2017; 12():1847-1856. PubMed ID: 28684907
[TBL] [Abstract][Full Text] [Related]
26. Outcomes and markers in the assessment of chronic obstructive pulmonary disease.
Jones PW; Agusti AG
Eur Respir J; 2006 Apr; 27(4):822-32. PubMed ID: 16585091
[TBL] [Abstract][Full Text] [Related]
27. Transcriptomics, proteomics and metabolomics driven biomarker discovery in COPD: an update.
Ghosh N; Dutta M; Singh B; Banerjee R; Bhattacharyya P; Chaudhury K
Expert Rev Mol Diagn; 2016 Aug; 16(8):897-913. PubMed ID: 27267972
[TBL] [Abstract][Full Text] [Related]
28. Search for biomarkers in chronic obstructive pulmonary disease: current status.
Nicholas BL
Curr Opin Pulm Med; 2013 Mar; 19(2):103-8. PubMed ID: 23361193
[TBL] [Abstract][Full Text] [Related]
29. Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement.
Wu AC; Kiley JP; Noel PJ; Amur S; Burchard EG; Clancy JP; Galanter J; Inada M; Jones TK; Kropski JA; Loyd JE; Nogee LM; Raby BA; Rogers AJ; Schwartz DA; Sin DD; Spira A; Weiss ST; Young LR; Himes BE
Am J Respir Crit Care Med; 2018 Dec; 198(12):e116-e136. PubMed ID: 30640517
[TBL] [Abstract][Full Text] [Related]
30. Systematic review on recent potential biomarkers of chronic obstructive pulmonary disease.
Aydindogan E; Penque D; Zoidakis J
Expert Rev Mol Diagn; 2019 Jan; 19(1):37-45. PubMed ID: 30560707
[No Abstract] [Full Text] [Related]
31. Molecular biomarkers for quantitative and discrete COPD phenotypes.
Bhattacharya S; Srisuma S; Demeo DL; Shapiro SD; Bueno R; Silverman EK; Reilly JJ; Mariani TJ
Am J Respir Cell Mol Biol; 2009 Mar; 40(3):359-67. PubMed ID: 18849563
[TBL] [Abstract][Full Text] [Related]
32. Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with COPD.
Aydin M; Altintas N; Cem Mutlu L; Bilir B; Oran M; Tülübaş F; Topçu B; Tayfur İ; Küçükyalçin V; Kaplan G; Gürel A
Clin Respir J; 2017 May; 11(3):318-327. PubMed ID: 26076870
[TBL] [Abstract][Full Text] [Related]
33. Current Approaches for Phenotyping as a Target for Precision Medicine in COPD Management.
Lopez-Campos JL; Centanni S
COPD; 2018 Apr; 15(2):108-117. PubMed ID: 29558165
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers, the control panel and personalized COPD medicine.
Agusti A; Gea J; Faner R
Respirology; 2016 Jan; 21(1):24-33. PubMed ID: 26172306
[TBL] [Abstract][Full Text] [Related]
35. Impact of Biomarkers on Personalized Medicine.
Carrigan P; Krahn T
Handb Exp Pharmacol; 2016; 232():285-311. PubMed ID: 26330258
[TBL] [Abstract][Full Text] [Related]
36. Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004.
Decramer M; Gosselink R; Rutten-Van Mölken M; Buffels J; Van Schayck O; Gevenois PA; Pellegrino R; Derom E; De Backer W
Thorax; 2005 Apr; 60(4):335-42. PubMed ID: 15790991
[TBL] [Abstract][Full Text] [Related]
37. Guideline for the management of chronic obstructive pulmonary disease (COPD): 2004 revision.
Bateman ED; Feldman C; O'Brien J; Plit M; Joubert JR;
S Afr Med J; 2004 Jul; 94(7 Pt 2):559-75. PubMed ID: 15283307
[TBL] [Abstract][Full Text] [Related]
38. Biomarkers in chronic obstructive pulmonary disease.
Sin DD; Vestbo J
Proc Am Thorac Soc; 2009 Sep; 6(6):543-5. PubMed ID: 19741266
[TBL] [Abstract][Full Text] [Related]
39. Proteoglycan 4 is a diagnostic biomarker for COPD.
Lee KY; Chuang HC; Chen TT; Liu WT; Su CL; Feng PH; Chiang LL; Bien MY; Ho SC
Int J Chron Obstruct Pulmon Dis; 2015; 10():1999-2007. PubMed ID: 26451097
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for FEV
Chen S; Wang C; Li B; Shi G; Li H; Zhang J; Gu Y; Zhou J; Song Y; Bai C
Int J Chron Obstruct Pulmon Dis; 2017; 12():435-442. PubMed ID: 28184155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
